Pulmonary, Critical Care, and Sleep Medicine

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. A Study to Assess Neuromuscular Ultrasound to Predict the Duration of Mechanical Ventilation.

   Rochester, Minn.

   The purpose of this study is to evaluate whether or not the diaphragm and abdominal muscle thickness determine the duration of mechanical ventilation in adult critically ill patients.

2. Submandibular Gland Needle Core Biopsy and Skin Punch Biopsy as Tissue Biomarkers for the Diagnosis and Monitoring of Disease Progression of Parkinson’s Disease and REM Sleep Behavior Disorder

   Scottsdale/Phoenix, Ariz.

   Determine 1) the magnitude of SMG and skin a-syn density change over time, 2) the

   improvement in adequate tissue acquisition doing bilateral SMG biopsies, 3) any laterality differences between

   SMG gland a-syn density, 4) correlate a-syn density and changes in density between SMG and skin biopsies

   Specific Aim 1. Determine, with bilateral submandibular gland (SMG) biopsies in 30 clinically

   diagnosed subjects with Parkinson’s disease (PD) and 20 clinically probable REM sleep behavior

   disorder (RBD) subjects whether bilateral biopsies improve the rate of acquisition of adequate

   glandular tissue, whether alpha-synuclein (a-syn) SMG pathology correlates with clinical severity

   and/or disease duration, and whether there is a left-right difference in the density of a-syn pathology.

   Specific Aim 2. Determine, with a second SMG biopsy in previously biopsied PD and RBD subjects,

   whether a-syn pathology density increases, decreases, or remains the same after a 1.5-2 year time

   interval and whether there is a correlation between a-syn SMG pathology and clinical and/or disease

   progression.

   Specific Aim 3. Determine whether a-syn pathology density in skin punch biopsies correlates

   with clinical measures and increases, decreases, or remains the same after a 1.5-2 year time

   interval, and whether the density and changes over time correlate with those found in SMG

   biopsies.

3. A Study to Evaluate Oxygen Supplementation Duration to Assess Resolution of Acute Hypoxic Respiratory Failure

   Rochester, Minn.

   The purpose of this study is to assess the feasibility, reliability and validity of oxygen supplementation duration as an intermediate outcome of resolution of acute hypoxic respiratory failure from all cause in comparison with PaO2/FiO2, SaO2/FiO2 ratio, and lung injury score trajectories in critically ill patients with acute respiratory failure.

4. COVID-19 and Acute Renal Failure

   Jacksonville, Fla., Scottsdale/Phoenix, Ariz., Rochester, Minn.

   The primary purpose of this study is to examine 1-year survival and rate of secondary infections in COVID-19 patients with and without acute kidney injury (AKI).

    

    

    

5. Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis

   Rochester, Minn.

   The purpose of this clinical trial is to determine if low dose naltrexone is effective in improving health-related quality of life (HRQoL) among patients with vasculitis. Although it is a pilot study, a placebo-controlled component is used because of the prominent placebo group effect seen in studies with self-reported subjective outcomes.

   Naltrexone is an FDA approved drug (for alcoholism) that has found widespread use "off-label" to treat pain and improve quality of life at much lower doses than are used for the approved indication. There are a few scientific studies in three conditions (fibromyalgia, Crohn's disease, and multiple sclerosis) that suggest that this drug has benefit and is safe. However, considering the extent of use in other conditions, and uncertainty about the mechanism of action study is needed in a diverse set of diseases, including vasculitis.

6. Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.

7. Influence of Immunosuppresion on Lung Iron Content in Pneumonia

   Scottsdale/Phoenix, Ariz.

   The purpose of the study is to see whether lung concentrations of iron and a protein that binds iron are influenced by the presence of pneumonia. Increased amounts of iron in the lungs may promote the growth or microorganisms and may influence the severity of lung injury caused by an infection. We are comparing the amount of iron that accumulates in the lungs in response to pneumonia in different types of patients.

8. Synucleinopathies

   Rochester, Minn.

   The goals of the study are to prospectively evaluate clinical and laboratory biomarkers of multiple system atrophy and Parkinson’s disease at early clinical disease, at a premotor stage (PAF), and even at a prodromal stage (RBD).

9. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of WSD0922-FU

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of WSD0922-FU in subjects with recurrent glioblastoma, IDH wildtype (GBM), anaplastic astrocytoma, IDH wildtype (AA) and CNS metastases of non-small cell lung cancer (NSCLC).

10. Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

    Rochester, Minn.

    The purpose of this trial is to study the effect of lutetium Lu 177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in the body (advanced). Radioactive drugs, such as lutetium Lu 177 dotatate, may carry radiation directly to tumor cells and may reduce harm to normal cells. Lutetium Lu 177 dotatate may be more effective than everolimus in shrinking or stabilizing advanced bronchial neuroendocrine tumors.